MedTrace Logo

Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive

NCT06078592 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-26

No results posted yet for this study

Summary

Comparison of Efficacy and Ocular Surface Disease Assessment between BRIDIN-plus Eye drops and Combigan Eye drops in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Conditions

Interventions

DRUG

BRIDIN-plus Eye drops

BRIDIN-plus Eye drops

DRUG

Combigan Eye drops

Combigan Eye drops

Sponsors & Collaborators

  • Hanlim Pharm. Co., Ltd.

    collaborator INDUSTRY

  • CHA University

    lead OTHER

Principal Investigators

  • Seungsoo Rho, MD, PhD · CHA Bundang Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-08
Primary Completion
2022-12-23
Completion
2022-12-23

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06078592 on ClinicalTrials.gov